Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough

One of the most malignant illnesses in psychiatry is opioid addiction. This disorder has resulted in a current epidemic of addiction, overdose, and death that continues in large part because of the lack of robust treatments and the surprising lack of utilization of the treatments that are available.

[1]  P. Krajči,et al.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial , 2017, JAMA psychiatry.

[2]  E. Nunes,et al.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial , 2017, The Lancet.

[3]  Thomas R Frieden,et al.  Medication-assisted therapies--tackling the opioid-overdose epidemic. , 2014, The New England journal of medicine.

[4]  S. Stahl.  Long-acting injectable antipsychotics: shall the last be first? , 2014, CNS Spectrums.

[5]  E. Nunes,et al.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial , 2011, The Lancet.

[6]  B P Smyth,et al.  Lapse and relapse following inpatient treatment of opiate dependence. , 2010, Irish medical journal.

[7]  S. Stahl,et al.  Stahl's essential psychopharmacology : neuroscientific basis and practical application , 2008 .

[8]  T. Robbins,et al.  Neural systems of reinforcement for drug addiction: from actions to habits to compulsion , 2005, Nature Neuroscience.

[9]  B. Sproule,et al.  Buprenorphine , 2005, Clinical pharmacokinetics.

[10]  T. George,et al.  The Neurobiology of Opioid Dependence: Implications for Treatment , 2002, Science & practice perspectives.

[11]  M. Stitzer,et al.  ONE-, THREE-, AND SIX-MONTH OUTCOMES AFTER BRIEF INPATIENT OPIOID DETOXIFICATION , 2001, The American journal of drug and alcohol abuse.

[12]  E. Nunes,et al.  [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial]. , 2012, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[13]  P. Marquet.  Pharmacology of High-Dose Buprenorphine , 2002 .